"This was compounded by major issues with patents held by a hostile competitor that threatened Moderna’s ability to turn a profit on anything it might manage to take to market, as well as major issues with its mRNA delivery system that led them to abandon any treatment that would require more than one dose because of toxicity concerns. T…
"This was compounded by major issues with patents held by a hostile competitor that threatened Moderna’s ability to turn a profit on anything it might manage to take to market, as well as major issues with its mRNA delivery system that led them to abandon any treatment that would require more than one dose because of toxicity concerns. THE LATTER ISSUE, THOUGH LARGELY FORGOTTEN AND/OR IGNORED BY MEDIA TODAY, SHOULD BE A MAJOR TOPIC IN THE COVID-19 BOOSTER DEBATE, GIVEN THAT THERE IS STILL NO EVIDENCE THAT MODERNA EVER RESOLVED THE TOXICITY ISSUE THAT AROSE IN MULTI-DOSE PRODUCTS."
"This was compounded by major issues with patents held by a hostile competitor that threatened Moderna’s ability to turn a profit on anything it might manage to take to market, as well as major issues with its mRNA delivery system that led them to abandon any treatment that would require more than one dose because of toxicity concerns. THE LATTER ISSUE, THOUGH LARGELY FORGOTTEN AND/OR IGNORED BY MEDIA TODAY, SHOULD BE A MAJOR TOPIC IN THE COVID-19 BOOSTER DEBATE, GIVEN THAT THERE IS STILL NO EVIDENCE THAT MODERNA EVER RESOLVED THE TOXICITY ISSUE THAT AROSE IN MULTI-DOSE PRODUCTS."